The objectives of this study was to examine the efficacy and safety of graded doses of c9, t11, t10, c12 CLA isomers on body composition, energy expenditure, lipid profile and hepatic biomarkers in hamsters. Male Golden Syrian hamsters (n=105) were randomized to seven treatments (control; 1, 2, 3% of c9, t11; 1, 2, 3% of t10, c12) for 28 days. Compared with control, 1% and 3% t10, c12 had lowered food intake with all three doses of t10, c12 lowering (p<0.0001) body fat mass (g). Groups fed with 1, 2, 3% t10, c12 and 3% c9, t11 treatments showed higher lean mass compared to control and other treatment groups. However, neither body weights, nor serum HDL or triglyceride levels differed across treatment groups. The 3% t10, c12 groups exhibited higher (p<0.0001) cholesterol and LDL-C levels compared to control or other treatment groups. The 2% and 3% t10, c12 groups also presented elevated ALT level (p<0.05). The present data suggest that 3% t10, c12 possess potential adverse effects on liver and posing unfavorable change in lipid profile.